As a U.S. partner at Pontifax, Jeffrey Rowbottom is responsible for expanding U.S. activities, including advising portfolio companies, identifying new investments, and building relationships with investors and strategic partners. Before joining Pontifax, he served in capital market roles for KKR, Goldman Sachs, Barclays Capital, and Citigroup. Rowbottom's focus on early-stage healthcare stems from his personal experience as a melanoma patient and from a family member's diagnosis with Ullrich congenital muscular dystrophy. He is a founding investor and business advisor for Rgenix and a senior advisor for The Trout Group. Rowbottom is on the boards of the Melanoma Research Alliance, Cure CMD, Project Renewal, and The Elisabeth Morrow School. He holds a B.S. in finance from SUNY at Albany and an M.B.A. from Columbia University.